Grigory Borisenko Net Worth

Grigory Borisenko biography

Grigory G. Borisenko, PhD is Director of the Company. He is the Investment Director of RUSNANO Management Company LLC, a Venture Capital & Private Equity management company in Russia. Mr. Borisenko has over 20 years of scientific, management and strategic experience in Life science field. Mr. Borisenko has specialized in investment projects in Life science since 2012, and from 2009 through 2012, he was a head of the pharmaceutical sector of the Department of Science and Technology Expertise at the state corporation, RUSNANO. Mr. Borisenko currently serves on the Board of Directors for two biotechnology companies, Atea Pharmaceuticals, Inc. and Adastra Pharmaceuticals, Inc., and from 2011 to 2014, served on the board of directors of Nearmedic Pharm LLC. Prior to his investment career, Mr. Borisenko held academic appointments with the University of Pittsburgh, Russian State Medical University and Institute of Medico-Biological Problems. He has co-authored over 50 peer-reviewed publications in leading biochemistry and cell biology journals. Mr. Borisenko received his M.S. and Ph.D. from the Russian State Medical University, and is a recipient of Fogarty International and International Fellowship Awards from NIH.

What's Grigory Borisenko's mailing address?

Grigory's mailing address filed with the SEC is 945, Concord Street, Framingham, Middlesex County, Massachusetts, 01701, United States.

What does Xenetic Biosciences Inc do?

xenetic biosciences (nasdaq: xbio) is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. xenetic's proprietary drug development platforms include polyxen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. xenetic's lead investigational product candidates include fda orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. xenetic is also working together with shire plc (formerly baxalta, baxter incorporated and baxter healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation factor viii. this collaboration relies on xenetic's polyxen technology to conjugate polysialic acid

Xenetic Biosciences Inc executives and stock owners

Xenetic Biosciences Inc executives and other stock owners filed with the SEC include:

• Jeffrey F. Eisenberg Esq.,
  CEO, Pres & Director
• James F. Parslow,
  CFO, COO & Corp. Sec.
• Dr. Curtis A. Lockshin,
  Chief Scientific Officer
• Colin Hill,
  Treasurer, Secretary, Director
• Grigory Borisenko,
  Director
• Adam Logal,
  Independent Director
• Dmitry Genkin,
  Independent Director
• James Callaway,
  Independent Director
• Roger Kornberg,
  Director
• Artur Isaev,
  Director
• Firdaus Dastoor,
  Director
• Timothy Cote,
  Director
• Curtis Lockshin,
  Chief Scientific Officer
• James Parslow,
  Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
• Jeffrey Eisenberg,
  Chief Executive Officer, Chief Operating Officer, Director
• Moshe Mizrahy,
  Director
• Darlene M Deptula Hicks,
  Director
• Alexey Andreevich Vinogradov,
  Director
• Michael Scott Maguire,
  CEO
• Edward J. Jr Benz,
  Director